Recent Insights into the Management of Behcet Syndrome

Ozguler Y., Ozdede A., HATEMİ G.

JOURNAL OF INFLAMMATION RESEARCH, cilt.14, ss.3429-3441, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 14
  • Basım Tarihi: 2021
  • Doi Numarası: 10.2147/jir.s285400
  • Dergi Adı: JOURNAL OF INFLAMMATION RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.3429-3441
  • Anahtar Kelimeler: Behcet syndrome, treatment, management, biologic agents, TNF inhibitor, DOUBLE-BLIND, MYCOPHENOLATE-MOFETIL, BIOSIMILAR INFLIXIMAB, CLINICAL-OUTCOMES, CYCLOSPORINE-A, CASE SERIES, DISEASE, PLACEBO, COLCHICINE, TRIAL
  • İstanbul Üniversitesi Adresli: Evet

Özet

Behcet syndrome (BS) is a multisystem vasculitis with variable vessel involvement that shows significant heterogeneity among patients in terms of clinical manifestations and disease course. Treatment choice and response are both influenced by this heterogeneity. BS treatments' main goals are to quickly suppress inflammatory exacerbations and prevent relapses in order to protect organ functions and provide good quality of life. Besides the long-term experience with steroids and traditional immunosuppressives, biologic drugs, especially TNF inhibitors, have gained increasing importance in the treatment of BS over the years. In this review, we aimed to give an overview of the studies with conventional and biological drugs with proven efficacy in the treatment of BS, as well as promising drugs and current management strategies according to clinical phenotypes.